Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells.

To investigate the role of PCBP1-AS1 in pancreatic cancer (PCa) liver metastasis and its underlying mechanisms. We analyzed the expression patterns of PCBP1-AS1, miR-125b-5p, and TNFAIP3 in PCa tissues, normal tissues, and peripheral blood exosomes. The relationships between these molecules and PCa pathological features, including liver metastasis, were examined. Dual-luciferase reporter assays confirmed the targeting interactions among PCBP1-AS1, miR-125b-5p, and TNFAIP3. We constructed PCa cell lines overexpressing miR-125b-5p and/or TNFAIP3, as well as PCBP1-AS1 and/or miR-125b-5p, to assess their effects on TNFAIP3 expression and cellular behaviors. The impact of exosomes from transfected or untransfected PCa cells on TNFAIP3 levels, NF-κB activation, and hepatic stellate cells (HSCs) to cancer-associated fibroblasts (CAFs) transformation was evaluated. A PCa liver metastasis model was constructed to study the effects of exosomes on HSCs activation. MiR-125b-5p was largely upregulated in PCa tissues and peripheral blood exosomes, with high expression correlating with advanced disease stage and liver metastasis. MiR-125b-5p promoted PCa progression by targeting TNFAIP3. Overexpression of miR-125b-5p further enhanced TNFAIP3 suppression, p-p65 activation, and HSCs-to-CAFs transformation induced by PCa-derived exosomes, while miR-125b-5p inhibition reversed these effects. Preconditioning with PCa-derived exosomes facilitated liver metastasis in vivo, with increased miR-125b-5p levels exacerbating metastasis by targeting TNFAIP3 and activating NF-κB. Reduced PCBP1-AS1 expression was associated with poorer survival in PCa patients and was significantly lower in tissues from patients with liver metastases. PCBP1-AS1 counteracted miR-125b-5p-mediated TNFAIP3 suppression and mitigated the tumor-promoting effects of miR-125b-5p. PCBP1-AS1 enhances TNFAIP3 expression by targeting miR-125b-5p, thereby inhibiting PCa progression. Reduced PCBP1-AS1 in PCa increases miR-125b-5p levels in exosomes, activating NF-κB and promoting HSCs-to-CAFs transformation, creating a favorable microenvironment for liver metastasis.

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) can extend survival, improve quality of life for patients

Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive malignancies of the digestive tract, with a 5-year survival rate below 13%. It often inf...

One in eight women is diagnosed with invasive breast cancer in the United States, according to the American Cancer Society. For Angela Firebaugh, becoming part of that statistic was unexpected, especi...

Background Hepatoid adenocarcinoma of the pancreas is a rare primary malignant tumor. According to few previous reports, with poor prognosis and atypical clinical features, hepatoid adenocarcinoma of the pancreas is easily misdiagnosed. Its pathological examination often shows similar morphological and immunohistochemical features to those of hepatocellular carcinoma. There is also insufficient clinical experience in the diagnosis and treatment of hepatoid adenocarcinoma. Case presentation A 45-year-old Asian woman, initially suspected to have late-stage pancreatic ductal adenocarcinoma, was admitted to our clinic with abdominal pain and jaundice. The magnetic resonance imaging scan showed a pancreatic head mass with enlarged retroperitoneal and portal lymph nodes. To confirm the diagnosis, a thorough evaluation of her medical history, clinical presentation, imaging findings, and laboratory tests was conducted. An endoscopic ultrasound-guided biopsy was performed, and the initial biopsy report suggested a neuroendocrine tumor. Based on this finding, a multidisciplinary team discussion was held, and the decision was made to proceed with radical surgery. Postoperative pathological examination unexpectedly revealed hepatoid adenocarcinoma of the pancreas, which led to a revision of the final clinical diagnosis. Following surgery, she received three cycles of postoperative adjuvant chemotherapy with a regimen of gemcitabine plus albumin-bound paclitaxel. Postoperative follow-up at 4 months indicated liver metastasis, for which she underwent microwave ablation. Subsequently, she was supplemented with adjuvant therapy combining durvalumab and S-1. At the time of writing, 16 months after her initial clinic visit, the patient remains alive without evidence of abdominal metastasis. Conclusion This case of hepatoid adenocarcinoma of the pancreas achieved a better prognosis through a comprehensive treatment based on surgery after multidisciplinary team discussion, giving the patient hope for long-term survival. The multidisciplinary team, in the form of multidisciplinary experts coming together to discuss the patient’s condition, changed the patient’s treatment decision, which may be another option when it comes to complex cases.

Pancreatic cancer (PC) is a highly aggressive malignancy associated with a poor prognosis. Its clinical management is particularly challenging due to …

The largest repository of validated, free and subject-focused e-publications and online seminars in analytical science covering latest techniques, equipment, original research, editorials, and industr...

Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells.

Joshua Lang: The Worst Medical Mistake I've Ever Made / cancer, Joshua Lang, OncoDaily, Oncology, Pancreatic neuroendocrine

Acidosis can trigger metabolic changes in pancreatic cancer cells that contribute to tumor growth, metastasis, and treatment resistance.

Dr Peter Kok-Ting Wan, PhD, postdoctoral researcher at the Department of Oncology, has been awarded a prestigious fellowship from Pancreatic Cancer UK to develop a new immunotherapy for pancreatic can...

What’s new in the treatment of pancreatic cancer? Pancreatic cancer researcher Shubham Pant, M.D., shares three recent advances.

Background Pancreatic cancer (PANC) is often diagnosed at late stages due to the absence of specific early symptoms, resulting in one of the highest cancer mortality rates. While imaging modalities su...

Diabetes mellitus (DM) represents a significant global public health challenge, as economic development and changes in modern dietary habits have contributed to a rising prevalence of DM patients. Pancreatic cancer (PC), a highly aggressive malignancy, exhibits a 5-year survival rate of approximately 10%. The intricate and perilous relationship between DM and the onset and progression of PC is increasingly being elucidated, revealing a complex underlying network that encompasses multiple dimensions, including molecular signaling, metabolism, endocrinology, immunity, microbiota, and tumor microenvironment formation. Consequently, this review aims to delineate the overarching framework of the extensive relational network between DM and PC, focusing on the aforementioned aspects. Specifically, this review highlights the promoting effects of DM on the carcinogenic process of PC, emphasizing the complexity of the DM-PC interaction and identifying potential therapeutic targets for intervention. Graphic abstract

Femtosecond laser acts on collagen for selective ablation leaving healthy tissue intact.

450Background: Pancreatic cancer (PC) remains one of the deadliest malignancies, due to late-stage presentation and limited risk-reduction strategies. Certain high-penetrance germline variants increas...

This study attempts to determine the long-term oncological outcome of minimally invasive left pancreatectomy vs open left pancreatectomy in patients with upfront resectable left-sided pancreatic cance...

374Background: Pancreatic cancer is an aggressive disease which requires comprehensive care. Complex treatment paradigms require coordination of care amongst medical oncologists, radiation oncologists...

Innovative dual treatment shows promise in tackling deadly cancer

Study Demonstrated a Sensitivity of 100% and Specificity of 95%Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early dete...